Understanding the role of MRAs in management of heart failure with Cardiologist Dr Rajeev Agarwala
Designated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have gone into disrepute, while many others have been found to be useful.
Recently, 2021 update on the 2017 ACC expert consensus decision pathway has upgraded mineralocorticoid receptor antagonist (MRA) as a class 1 indication for the treatment of Heart failure with reduced ejection fraction.
Dr Rajeev Agarwala , an eminent cardiologist explains the role of MRAs in the management of heart failure.
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)